Illumina (ILMN) After Its MRD Workflow Launch With Valuation Still In Focus

Simply Wall St.11-12

Why Illumina's MRD Duplex Workflow Matters For The Stock Illumina (ILMN) has put its molecular residual disease research ambitions front and center with an early access duplex sequencing workflow that...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment